Researchers found that combining two medications, Taltz (ixekizumab) and Zepbound (tirzepatide), significantly improves outcomes for adults with psoriatic disease and obesity. In a year-long study, participants who took both medications experienced better control of their psoriasis and psoriatic arthritis symptoms, along with improvements in weight and metabolic health. Specifically, 30.6% of those on the combination therapy achieved complete skin clearance and at least 10% weight loss, compared to just 4.4% with Taltz alone. Similarly, 39.2% of participants saw a significant reduction in psoriatic arthritis activity alongside weight loss, compared to only 1.7% with Taltz alone.

This matters for anyone looking to age well, especially if they struggle with psoriatic conditions and obesity. The findings indicate that using Taltz and Zepbound together can lead to substantial benefits, such as improved muscle strength and reduced systemic inflammation, which are crucial for maintaining overall health as you age. The study involved 545 adults, making it a robust exploration of how these medications can work together to enhance health outcomes.

The research is based on Phase 3b trials, which are designed to provide strong evidence of effectiveness and safety but are still considered early-stage. While the results are promising, they are not yet definitive proof of long-term benefits in the general population. Future presentations and peer-reviewed publications will provide more detailed insights into these findings.

For those considering these treatments, it’s essential to consult with a healthcare provider to discuss individual circumstances and potential benefits, especially since both medications come with specific safety considerations.